Effect of bisoprolol on perioperative complications in chronic heart failure after surgery (Cardiac Insufficiency Bisoprolol Study II (CIBIS II)).

In patients with coronary artery disease undergoing noncardiac surgery, beta-blockers decrease perioperative mortality and nonfatal myocardial infarction. It is presently unknown whether beta-blockers reduce perioperative risk in patients with chronic heart failure. Thus, data of the CIBIS II study were analyzed regarding the effect of bisoprolol on perioperative outcome in patients with moderate to severe heart failure. A total of 2647 patients with heart failure in New York Heart Association (NYHA) class III-IV and left ventricular ejection fraction < or =35% were randomized to bisoprolol or placebo in a double-blind randomized study. Of these patients, 165 underwent surgery (bisoprolol, n = 87; placebo, n = 78). In patients undergoing surgery, mortality was not different between the placebo- and bisoprolol-treated group (7.7% vs 5.8%, p = 0.76). Neither postoperative hospital admission (placebo, 24.4%; bisoprolol, 34.5%, p = 0.17) nor time to postoperative hospital admission (placebo, < or =30 days, n = 2; 31-180 days, n=11; >180 days, n = 6; bisoprolol, n = 9/ 10/11; p = 0.14) were reduced by bisoprolol. Compared to coronary artery disease, perioperative beta-blockade has little effect in patients with chronic heart failure. Therefore, a controlled randomized trial with perioperative beta-blocker treatment in heart failure patients is warranted to further test this hypothesis.

[1]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[2]  L Goldman,et al.  Multifactorial index of cardiac risk in noncardiac surgical procedures. , 1977, The New England journal of medicine.

[3]  D. Mangano.  Perioperative Cardiac Morbidity , 1990 .

[4]  W. Castelli,et al.  Epidemiology of coronary heart disease: the Framingham study. , 1984, The American journal of medicine.

[5]  K. Davis,et al.  Risk of noncardiac operation in patients with defined coronary disease: The Coronary Artery Surgery Study (CASS) registry experience. , 1986, Annals of Thoracic Surgery.

[6]  E. Antman,et al.  ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery---executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluat , 2002, Circulation.

[7]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[8]  R. Salamon,et al.  Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[9]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[10]  E. Kramer,et al.  The value of the radionuclide angiogram in the prediction of perioperative myocardial infarction in patients undergoing lower extremity revascularization procedures. , 1985, Circulation.

[11]  Gries,et al.  Perioperative catecholamine changes in cardiac risk patients , 1999, European journal of clinical investigation.

[12]  E F Cook,et al.  Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. , 1999, Circulation.

[13]  R. Adolph,et al.  Cardiac prognosis in noncardiac geriatric surgery. , 1985, Annals of internal medicine.

[14]  P. Rehak,et al.  Perioperative myocardial cell injury: the role of troponins. , 1997, British journal of anaesthesia.

[15]  T. H. Lee,et al.  Reducing cardiac risk in noncardiac surgery. , 1999, The New England journal of medicine.

[16]  Thomas O. Staiger,et al.  Self-reported exercise tolerance and the risk of serious perioperative complications. , 1999, Archives of internal medicine.

[17]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[18]  A. Wallace,et al.  Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. , 1996, The New England journal of medicine.

[19]  Jeroen J. Bax,et al.  The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. , 1999, The New England journal of medicine.

[20]  K. Posner,et al.  Adverse cardiac outcomes after noncardiac surgery in patients with prior percutaneous transluminal coronary angioplasty. , 1999, Anesthesia and analgesia.

[21]  E. Vartiainen,et al.  Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. , 1999, Circulation.

[22]  L. Fleisher,et al.  LOWERING CARDIAC RISK IN NONCARDIAC SURGERY , 2001 .

[23]  Kannel Wb.  Need and prospects for prevention of cardiac failure. , 1996 .

[24]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[25]  Prophylactic Atenolol Reduces Postoperative Myocardial Ischemia , 1998 .

[26]  S. L. Murphy.  Deaths: final data for 1998. , 2000, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[27]  Chris Shaw,et al.  Interim 2003-based national population projections for the United Kingdom and constituent countries. , 2004, Population trends.

[28]  H. Kehlet,et al.  Prediction of cardiac risk in non-cardiac surgery. , 1987, European heart journal.